Genentech Plans Avastin Breast Cancer Resubmission In August
This article was originally published in The Pink Sheet Daily
Executive Summary
Company expects a six-month review for the supplemental claim, setting early 2008 for potential FDA approval.
You may also be interested in...
Avastin Makes Headway Into Renal Cell Carcinoma
Roche unveils positive metastatic RCC data from the highly anticipated AVOREN study at American Society of Clinical Oncology meeting.
Roche Considers Pricing Flexibility For Avastin In Europe
Similar to Genentech’s price cap on Avastin in the U.S., Roche is evaluating “creative” pricing approaches following breast cancer approval.
Genentech To Resubmit Avastin sBLA In Mid-2007
FDA is seeking substantially more information than expected from an NCI-sponsored trial for first-line treatment of metastatic breast cancer, the company says.